SYGNIS is granted the European and US patent for a very versatile and efficient drug screening platform

18-Jan-2013 - Germany

SYGNIS Pharma AG has been granted the European and US patent for a new basic technology for the detection of protein-protein interactions, a screening platform for the development of novel drugs. 

Protein-protein interactions falls within the scope of proteomics, a field that is growing in importance for research into new customized drugs. SYGNIS’ new platform  can be used to improve the characterization of new drugs in development and identification of new therapeutic targets. SYGNIS’ technology will increase the potential for generating better drugs within the customized drug development field.

Other news from the department research and development

Most read news

More news from our other portals

Last viewed contents

Sirius Genomics Announces Appointment of Senior Director of Business Development

LFE Laboratorium für industrielle Forschung GmbH & Co. Entwicklungs KG - Bruchköbel, Germany

LFE Laboratorium für industrielle Forschung GmbH & Co. Entwicklungs KG - Bruchköbel, Germany

Andromeda Biotech Successfully Completes Patient Recruitment in Phase III Trials for DiaPep277 for Type 1 Diabetes

Bonnie Bassler and Martin Wikelski receive Max Planck Research Award - Scientists honoured for their pioneering research into the sensory perception of organisms

Bonnie Bassler and Martin Wikelski receive Max Planck Research Award - Scientists honoured for their pioneering research into the sensory perception of organisms

Stora Enso and Gasum to make renewable energy from wastewater in Sweden

LDC and HZI enter partnership for the discovery of new drugs against multi-resistant bacteria

LDC and HZI enter partnership for the discovery of new drugs against multi-resistant bacteria

New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction

New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction

Generex Biotechnology and Pevion Biotech announce plans for immunotherapeutic vaccine collaboration

Successful Outcome from European Clinical Pharmacokinetic Study Comparing SUBA-Itraconazole with Sporanox - HalcyGen to begin Marketing Authorisation Application for Regulators in Europe

Eschbach receives the Best of Industry Award for Artificial Intelligence for the second time in a row - "AI technologies are increasingly becoming an integral part of process management..."

Eschbach receives the Best of Industry Award for Artificial Intelligence for the second time in a row - "AI technologies are increasingly becoming an integral part of process management..."

Antibiotic-Resistant Bacteria Have Evolved a Unique Chemical Mechanism, New Discovery Reveals

UF study strengthens concerns about long-term use of certain painkillers